Avanos Medical: 40¢ Per Share Benefit Expected - News Directory 3

Avanos Medical: 40¢ Per Share Benefit Expected

February 24, 2025 Catherine Williams Business
News Context
At a glance
  • (AVNS) is expected to report a substantial increase in quarterly revenue, data collected by secondary sources suggest.
  • The revenue increase – expected to be 2.3% – equates to approximately 177.25 million Dollars, up from 173.3 million in last year's fiscal quarter.
  • Based on current average benchmarks from analysts, the recommendation leaned more towards "hold," with no "strong buy" recommendations.
Original source: boursorama.com

Avanos Medical Inc Poised for Quarterly Revenue Growth

Table of Contents

Alpharetta, Georgia-based Avanos Medical Inc. (AVNS) is expected to report a substantial increase in quarterly revenue, data collected by secondary sources suggest. According to an automated summary, the medical corporation in Alpharetta GA should publish an earnings report for the period ending on December 31, 2024. The report is slated for release on February 26. For medical device manufacturers in the U.S., Q4 is a high-activity period characterized by the preparation of fourth-quarter forecasts, their subsequent filing, and the release of final quarter data during the first two months of the new year. Quarterly reports not only indicate the performance of each quarter but also serve as a reliable indicator of the company’s economic health. Despite the various factors that can affect these reports, the corporate annual reports marked by reliability and dependability of the economic outcomes.

Revenue Projections and Analyst Estimates

The revenue increase – expected to be 2.3% – equates to approximately 177.25 million Dollars, up from 173.3 million in last year’s fiscal quarter. Based on forecasts by LSEG analysts, “the average estimate of 2 analysts based on LSEG data”, this level signifies a modest yet positive trend as medical device companies expand services despite persistent economic volatility. The estimates project that the net income or earnings per share (EPS) for Avanos Medical Inc. will be approximately 40 cents per share. This aligns with the company’s earlier forecasts made on October 30, 2024, which anticipated earnings in the range of 38 to 43 cents per share, for the period ending on December 31, 2024. A November 2024 guidance from a major pharmaceutical company projected a solid fiscal year, encouraging similar projections from other companies in the sector. This trend opposes a bearish economic market outlook in some sectors. Despite external economic scenarios, the healthcare services sector generally displays resilience and promising growth trends.

Analyst Recommendations and Market Sentiment

Investor sentiment towards Avanos Medical Inc. appears to be cautious. Based on current average benchmarks from analysts, the recommendation leaned more towards “hold,” with no “strong buy” recommendations. According to statements by two unnamed analysts, there is a universal sentiment to be cautious given the market volatility which may indicate upcoming periods of caution.. On the flip side, two analysts suggested maintaining current positions due to potential profit margins.
Analyst forecasts concluded that of the aggregated estimates, the others suggested neither selling the shares nor purchasing new shares during Forecasts from October 30 anticipate gross profit margins of 59%. Monthly stock fluctuations and quarterly surveys corroborate analysts’ predictions.

Market Performance and Price Targets

The median price target for Avanos Medical Inc. on Wall Street, calculated on February 24, 2024, estimated a 12-month forecast, projecting stock prices around 20.00 Dollars, elevated from December 24, of around 15.45 Dollars based on forecasts by LSEG analysts. The anticipated robust Q4 covering projections provide a reliable indicator of share price movements, thus promising upward growth.

Recent Developments and Implications

The anticipated increase results from other recent medical trends, including, new product launches, strategic partnerships, and an increasing demand for health equipment. Introduced in October 2024, the company’s latest medical devices have reportedly seen brisk sales across the US, with specialized medical devices creating new market niches. The seasonality and compliance clause on the forecasts associating increased December activity.

The Road Ahead

“The average estimate of profits by analysts

by analysts has remained unchanged in the last 3 months.”

“All figures are expressed in US dollars, unless otherwise indicated.”

LSEG Analysts

Despite growing optimism based on informative data, economic uncertainties persist. Mid to large-scale business enterprises in volatile provinces must also prepare for unexpected market changes.

Evaluating Analysts’ Views

While investors and analysts remain cautiously optimistic, it’s essential to reconsider ongoing economic trends that can affect stock movement. Analysts suggested no significant market moves in the upcoming forecasted period. These points and arguments would, however, continue to receive investigator scrutiny and the results arrived assessing previous predictions can yield further insights

Investment Insights

Based on seasonal data, markets present appropriate investment opportunities. Simultaneously, investors must carefully assess forecasts, reflecting accurate data.

This summary was generated by machine on February 24 at 2:03 p.m. GMT.

Q&A: Avanos Medical Inc. Poised for Quarterly Revenue Growth

What is Avanos Medical Inc.’s anticipated revenue growth for the upcoming quarter?

Avanos Medical Inc. (AVNS) is expected to report a significant increase in its quarterly revenue for the period ending December 31, 2024. Analyst forecasts suggest a 2.3% growth, raising projected revenue to approximately $177.25 million from $173.3 million in the previous fiscal quarter. This growth indicates a modest yet positive trend for medical device companies amid ongoing economic volatility.

  • Key insight: Avanos Medical’s Q4 forecast reflects the industry’s resilience, projecting steady growth despite market fluctuations.

When will Avanos Medical Inc. release its earnings report for Q4 2024?

The earnings report for Avanos Medical Inc. for the fourth quarter of 2024 is scheduled to be released on Febuary 26, 2025.this release is important as Q4 is a high-activity period for medical device manufacturers in the U.S., involving the readiness and filing of fourth-quarter forecasts and the release of final quarter data in the first two months of the new year.

  • Professional tip: Investors should consider reviewing these reports closely to gauge the company’s performance and its potential economic impact.

What are the analyst estimates for Avanos Medical Inc.’s earnings per share (EPS) and gross profit margins?

LSEG analyst forecasts estimate Avanos Medical Inc.’s net income or earnings per share (EPS) for Q4 2024 to be approximately 40 cents per share. These projections are consistent with the company’s earlier forecasts from October 30, 2024, which anticipated EPS in the range of 38 to 43 cents per share. Additionally, October forecasts anticipated gross profit margins of 59%. Analysts expressed caution due to market volatility but maintained that the healthcare sector generally shows resilience and growth.

  • Actionable insight: Investors can use this information to make informed decisions about their positions in Avanos Medical stock, considering both the revenue growth and profit margins.

What is the current market sentiment and analyst recommendation for Avanos Medical Inc.?

Investor sentiment towards Avanos Medical Inc. currently leans towards a “hold” recommendation, with no “strong buy” recommendations in place. Analysts suggest caution due to market volatility. Despite this,two analysts have recommended maintaining current positions due to potential profit margins,as reflected in forecasts from October 30,2024.

  • market sentiment: Avanos Medical’s stock should be viewed as stable, with the potential for profit margins supporting current stock positions.

What are the price targets for Avanos Medical Inc. stock?

As of February 24, 2024, the median price target for Avanos Medical Inc. on Wall Street estimated a 12-month forecast projecting stock prices around $20.00, an increase from approximately $15.45 as of December 24, based on LSEG analyst forecasts. The anticipated robust Q4 coverage provides a reliable indicator of share price movements, suggesting potential upward growth.

  • Investment insight: Given the projected price targets, investors might consider monitoring Avanos Medical’s stock for growth opportunities.

What recent developments could impact Avanos Medical Inc.’s revenue growth?

Avanos Medical Inc.’s anticipated growth can be attributed to recent trends, including new product launches, strategic partnerships, and an increasing demand for health equipment. The company’s latest medical devices, introduced in October 2024, have seen brisk sales across the U.S., creating new market niches and aligning with seasonal increases in December activity.

  • Key advancement: New product launches and partnerships are crucial for Avanos Medical’s growth strategy,highlighting the importance of innovation in the healthcare sector.

What are the long-term outlooks for Avanos Medical Inc. amid economic uncertainties?

Despite growing optimism based on recent data, economic uncertainties persist. Analysts have remained cautious about important market moves in the upcoming forecasted period,maintaining their average profit estimates unchanged for the last three months. Investors should keep a close eye on economic trends that may impact stock movements.

  • Strategic approach: Companies should prepare for unexpected market changes,especially in volatile sectors,by reviewing ongoing economic trends.

How should investors approach investment opportunities in Avanos Medical Inc.?

Investors should consider seasonal data and market trends to identify appropriate investment opportunities. It is indeed critically important to assess forecasts and reflect accurate data to ensure informed investment decisions. Cautious optimism remains key, given the company’s steady forecasts and resilience in the healthcare sector.

  • Investment strategy: Careful evaluation of forecasts and market conditions is essential for successful investments in companies like Avanos Medical.

This article has been crafted to provide extensive insights into Avanos Medical Inc.’s anticipated revenue growth and market position, drawing on data and updates without referencing time-sensitive information.

, , , , , , , , , ,